GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hunan Fangsheng Pharmaceutical Co Ltd (SHSE:603998) » Definitions » Return-on-Tangible-Equity

Hunan Fangsheng Pharmaceutical Co (SHSE:603998) Return-on-Tangible-Equity : 35.73% (As of Sep. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Hunan Fangsheng Pharmaceutical Co Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Hunan Fangsheng Pharmaceutical Co's annualized net income for the quarter that ended in Sep. 2024 was ¥365 Mil. Hunan Fangsheng Pharmaceutical Co's average shareholder tangible equity for the quarter that ended in Sep. 2024 was ¥1,022 Mil. Therefore, Hunan Fangsheng Pharmaceutical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2024 was 35.73%.

The historical rank and industry rank for Hunan Fangsheng Pharmaceutical Co's Return-on-Tangible-Equity or its related term are showing as below:

SHSE:603998' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 8.33   Med: 11.21   Max: 39.78
Current: 28.18

During the past 13 years, Hunan Fangsheng Pharmaceutical Co's highest Return-on-Tangible-Equity was 39.78%. The lowest was 8.33%. And the median was 11.21%.

SHSE:603998's Return-on-Tangible-Equity is ranked better than
88.06% of 913 companies
in the Drug Manufacturers industry
Industry Median: 6.4 vs SHSE:603998: 28.18

Hunan Fangsheng Pharmaceutical Co Return-on-Tangible-Equity Historical Data

The historical data trend for Hunan Fangsheng Pharmaceutical Co's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hunan Fangsheng Pharmaceutical Co Return-on-Tangible-Equity Chart

Hunan Fangsheng Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.13 9.77 11.29 39.78 20.92

Hunan Fangsheng Pharmaceutical Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.14 19.85 29.41 27.04 35.73

Competitive Comparison of Hunan Fangsheng Pharmaceutical Co's Return-on-Tangible-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Fangsheng Pharmaceutical Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hunan Fangsheng Pharmaceutical Co's Return-on-Tangible-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hunan Fangsheng Pharmaceutical Co's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Hunan Fangsheng Pharmaceutical Co's Return-on-Tangible-Equity falls into.



Hunan Fangsheng Pharmaceutical Co Return-on-Tangible-Equity Calculation

Hunan Fangsheng Pharmaceutical Co's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=186.823/( (869.975+916.011 )/ 2 )
=186.823/892.993
=20.92 %

Hunan Fangsheng Pharmaceutical Co's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Sep. 2024 )  (Q: Jun. 2024 )(Q: Sep. 2024 )
=365.176/( (978.262+1065.739)/ 2 )
=365.176/1022.0005
=35.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Sep. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Hunan Fangsheng Pharmaceutical Co  (SHSE:603998) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Hunan Fangsheng Pharmaceutical Co Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Hunan Fangsheng Pharmaceutical Co's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Hunan Fangsheng Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Lu days Road 19, Yuelu District, Hunan Province, CHN, 410205
Hunan Fangsheng Pharmaceutical Co Ltd is engaged in pharmaceutical business. The company's business scope covers the production and sales of tablets, capsules, granules, oral suspension, powder, suppository, powder-injection, tinctures, spray lotion, small volume injections, and bulk pharmaceutical chemicals. Its product offerings include Cefixime Tablets, Cefpiramide for Injection, Cefprozil Tablets, Fleroxacin Dispersible Tablets, and others.
Executives
He Shi senior management
Xiao Han Qing senior management
Liu Xin He senior management
Chen Bo Director
Chen Ai Chun Director
Li Zhi Heng senior management
Zhou Wei En senior management
Zhang Qing Hua Director
Huang Min Director
Zhou Xiao Li senior management
Fang Jin Cheng Director
Fang Chuan Long Supervisors
Tan Yuan Ming Director

Hunan Fangsheng Pharmaceutical Co Headlines

No Headlines